Dr Clara Alsinet-Armengol | Postdoctoral Fellow

Alsinet-Armengol, Clara

I am a postdoctoral fellow in the Experimental Cancer Genetics team. May main focus is the functional characterization of known and novel cancer genes using human induced Pluripotent Stem Cells and CRISPR-Cas9.

High-throughput sequencing efforts are uncovering the mutation profiles associated to cancer in a comprehensive and unbiased fashion. Nevertheless, further analyses of the identified alterations are necessary to highlight those genes implicated in disease development, as well as, those with therapeutical potential. Recently, the team generated a list of candidate genes commonly lost in cancer based on the analysis of >7500 tumor samples across 28 tissues. To uncover the functional impact of the loss of these genes we are generating a panel of knock-out isogenic iPS cell lines using CRISPR-Cas9 and we will perform high-throughput genetic and drug screenings on these lines. Overall, this study will identify molecular interactions of the selected cancer-related genes thus revealing potential new roles and candidate therapies.

Publications

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

Alsinet-Armengol, Clara
Clara's Timeline
2013

Start of my first Postdoc at the Wellcome Trust Sanger Institute in Cambridge, UK

PhD in Biomedicine from the University of Barcelona

2011

Visiting Researcher at the Icahn School of Medicine at Mount Sinai, New York

2008

Post-Graduate in Molecular and Cellular Biology at the University of Barcelona

2006

Education Aborad Program student at the University of California, Davis

2005

Major in Biotechnology at the Autonomous University of Barcelona